Skip to main content
All lobbying filings

BRIDGEBIO PHARMA, INC.

BRIDGEBIO PHARMA, INC. filed a Q2 report for BRIDGEBIO PHARMA, INC. on July 17, 2025.

Lobbying for BRIDGEBIO PHARMA, INC. · Biotech company

All filings by BRIDGEBIO PHARMA, INC. · Everything BRIDGEBIO PHARMA, INC. has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 17, 2025
Expenses
$320,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
California

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1
Pharmacy

Give Kids a Chance Act of 2025 - H.R. 1262; S 932 Camerons Law - H.R. 1414 Tax Provisions in H.R. 1 - One Big Beautiful Bill Act - R&D tax credit, bonus depreciation, interest deduction, Provisions related to PBM Reform in H.R. 1 - One Big Beautiful Bill Act ORPHAN Cures Act - included in H.R. 1 - One Big Beautiful Bill Act Orphan drug policies Scientific EXPERT Act of 2025 - H.R. 1532; S. 822

 Bills named in this filing 5

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem